German biotech firm CureVac has taken Moderna to court in Delaware, claiming the American drugmaker’s blockbuster Spikevax ...

Moderna is working to build a seasonal vaccines portfolio to spur growth. The FDA this week said it won’t review the biotech’s flu vaccine candidate. But, as demand for coronavirus vaccines waned ...

Moderna Inc.’s shares plunged after U.S. regulators refused to review its novel mRNA flu vaccine, dealing a major blow to the company as it seeks more products beyond its COVID shot. The U.S. Food and ...